New hope for rare cervical cancer: immunotherapy plus chemo-radiation shows promise
NCT ID NCT07336147
First seen Jan 17, 2026 · Last updated May 14, 2026 · Updated 17 times
Summary
This study tests whether adding the immunotherapy drug dostarlimab to standard chemotherapy and radiation can help women with a rare, aggressive cervical cancer live longer without the disease getting worse. About 45 women with previously untreated cancer will receive the combination in a specific sequence. The goal is to improve the 2-year progression-free survival rate from 57% to 75%.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FEMALE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chang Gung Memorial Hospital, Linkou Branch
RECRUITINGTaoyuan, Taiwan, 333, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.